SA cancer therapies 2 - medical therapies

0.0(0)
Studied by 0 people
call kaiCall Kai
learnLearn
examPractice Test
spaced repetitionSpaced Repetition
heart puzzleMatch
flashcardsFlashcards
GameKnowt Play
Card Sorting

1/33

encourage image

There's no tags or description

Looks like no tags are added yet.

34 Terms

1
New cards

What is chemoherapy?

Genotoxic (DNA damaging) tx of dx using chemical substances —> esp tx of cancer by cytotoxic & other drugs

2
New cards

What are the different ways chemotherapy can be used?

  • Primary chemotherapy —> common with lymphoma (sole anti-cancer tx)

  • Adjuvant Chemotherapy —> after surgery to remove any mets

  • Neoadjuvant chemotherapy —> given before surgery to shrink tumour & incr chance of successful resection (mast cell tumour)


3
New cards

How does chemotherapy work?

Active against rapidly proliferating tissues

does not specifically target cancer cells —> cannot differentiate between cancer cell & normal cell

those not actively dividing are relatively resistant to chemo

4
New cards

At what time point is chemotherapy most likely to be effective?

Before a mass can be identified —> the more cells the more likely there is going to be a resistant one

5
New cards

What are the factors that affect chemotherapy success?

  • Tumour cell heterogeneity (evolution of resistance) —> linked to tumour size

  • Inherent tumour sensitivity

    • Origin tissue

    • Growth fraction

  • Drug dosage

  • Tumour blood supply / oxygenation

  • Interval between txs

  • Other drugs (steroids when treating a lymphoma)


6
New cards

How do you minimise drug resistance?

  • Treat as early as poss

  • Follow properly evaluated protocols

  • Use correct doses

  • Avoid pre-tx w/ drugs that induce resistance

  • @ relapse, act ASAP


7
New cards

What considerations need to be made about drug pharmacology?

  • Administration —> dose & ability of oral drugs to get in blood stream

  • Distribution —> size of molecule & blood barriers

  • Metabolism —> drug activation / deactivation e.g. glutathionine

  • Excretion —> clearance —> abnomral GFR correlates w/ adverse effects of some drugs

    (issues with animals with hepatic and renal problems)


8
New cards

How do you dose obese patients?

Estimating lean weight

9
New cards

Other than obesity, what other types of patients pose dosing problems?

  • Collies & others w/ known drug sens

  • Animals w/ hepatic functional compromise

  • Animals w/ reduced renal function


10
New cards

What needs to be considered when choosing a chemotherapy agent?

  • Indication?

  • Evidence of benefit?

  • Often palliative (longer or shorter term)

  • Signalment, ADME, co-morbidities


11
New cards

When is single agent chemotherapy used?

  • Sensitive tumours —> Transmissible venereal tumour (TVT)

  • Tends to select rapidly for drug resistance

    • selection pressure high → rapid dominance of progeny of resistant cells


12
New cards

How does the risk of toxicity differ between sequential and combined polychemotherapy?

combined (several drugs given @ diff times) > sequential (several drugs given same time)

<p>combined <em>(several drugs given @ diff times) </em>&gt; sequential <em>(several drugs given same time)</em></p>
13
New cards

What routes of administration are used for chemotherapy?

  • Oral

  • IV

    • Bolus (rapidly)

    • Infusion (slowly)

  • IM/SC

  • Intracavitary

  • try to avoid topical & intratumoural agents —> incr risk of environmental & personnel exposure

    (always wear appropriate PPE when doing this and consider environmental risk)


14
New cards

How is dosing worked out for patients?

  • Start at the maximum tolerated dose (will be the dose listed in protocol) —> reduce if there are adverse effects

  • Dosing based on body surface area —> correlates w/ liver/kidney blood supply (metabolic capacity) better than weight

  • For smaller patients (<10kg) some drugs are administered on mg/kg

    • carboplatin, doxorubicin, epirubicin

  • double check & record all doses & calculations


15
New cards

What is the interval between txs for?

  • Allow recovery of normal tissues

  • Rapidly dividing tissues e.g. bone marrow & GI tract tend to repair more rapidly than most tumours (treatments too close together leads to toxicity of normal tissue)


16
New cards

What needs to make up Pre-chemotherapy assessment?

  • Discuss tolerance of any previous tx

  • Assess patient

  • Assess tumour status

  • Biochem

  • Haematology prior to each tx —> neutros & platelets

    • neutropenic → acute bacterial infection from gram -ve bacteria in gut

  • Urinalysis start of tx , prior to cyclophosphamide


17
New cards

What are the different responses you can have to the therapy?

  • Complete remission CR - all lesions gone, no new lesions

  • Partial remission PR - ≥ 30% reduction in size, no new lesions

  • Stable disease SD - between PR and PD

  • Progressive disease PD - ≥20% increase or new lesions

  • (can only monitor this for primary and neoadjuvant chemo)

    • for adjuvant tx —> individual response assessment not poss


<ul><li><p>Complete remission CR - all lesions gone, no new lesions</p></li><li><p>Partial remission PR - ≥ 30% reduction in size, no new lesions</p></li><li><p>Stable disease SD - between PR and PD</p></li><li><p>Progressive disease PD - ≥20% increase or new lesions</p></li></ul><ul><li><p><em>(can only monitor this for primary and neoadjuvant chemo)</em></p><ul><li><p><em>for adjuvant tx —&gt; individual response assessment not poss</em></p></li></ul></li></ul><p></p>
18
New cards

How common are side effects from chemotherapy?

  • 30 – 50 % of patients have some side effects during tx course

  • Most side effects —> transient & self resolving

  • <10 % have side effects → hospitalisation

  • 1 – 2 % chance of death (usually sepsis)


19
New cards

What immediate toxicities (<24hrs) can you get?

What tx would you use for these?

  • Anaphylaxis/hypersensitivity —> dexamethasone IV, IVFT, H1 blocker, adrenaline

  • Cardiac arrhythmia

  • Emesis —> Metaclopromide or ondansetron


20
New cards

What is acute tumour lysis syndrome?

  • Rapid destruction of cancer cells in patients w/ large tumour burdens

  • First 24-48hrs

  • Electrolyte abnormalities

    • Hyperkalaemia

    • Hyperphosphatemia

    • Hypocalcemia

  • AKI


21
New cards

How would you deal with a patient with high tumour burdens?

  • Careful monitoring of at risk patient —> keep in the hospital for 24-48 hours

  • Early IVFT if you see signs

  • Management of AKI


22
New cards

What longer term side effects can you see?

  • Bone marrow low WBC count(7-10 days)

  • Alopecia —> uncommon, specific breeds

  • Gastrointestinal —> does not usually last longer than the first 4 days

    (Rapidly dividing cells most affected)


23
New cards

What signs will you see w/ GI tox?

  • 1-5d post tx

  • Anorexia, nausea, V+, D+

  • Disrupted mucosal barrier w/ neutropenia incr risk of sepsis (bacterial translocation)


24
New cards

How can you manage GI toxicity initially?

  • Maropitant —> dispense for home use to prevent vomiting

  • Pre-tx fasting reduces D+

  • Consider dispensing smectite in case of D+ (VBS clay)

  • (probiotics ineffective)


25
New cards

What do you do if signs of GI toxicity last longer than 24 – 48 hours?

(patient unwell/off food & owner concerned?)

Supportive tx 48-72hrs:

  • IVFT

  • Anti-emetics —> metoclopramide (for nausea), ondansetron

  • D+ → maropitant, smectite

  • Be aware of incr risk of sepsis if patients become neutropenic


26
New cards

Describe pyrexic neutropenic patients 7-10d post chemotherapy and how to treat them

  • Medical emergency —> may be septic

  • Translocation of bacteria from patient’s own GI flora

  • Hospitalisation until systemically well

  • Stop all cytotoxic drugs —> dose reduction next time

  • Barrier nurse & aseptic techniques

  • Supportive therapy —> bactericidal ABs


27
New cards

How does your approach differ depending on the amount of neutrophils?

  • Neutrophil count <1x109/L

    • ABs (amox/clav 20mg/kg bid 7d or TMPS)

    • Drug discontinuation (if on tablets)

    • Check temp

    • Subsequent dose reduction

  • Neutrophil count 1-1.5x109/L

    • If next dose due will need to be delayed

    • No ABs unless good reason

  • Neutrophil count 1.5-2.5x109/L

    • Dose may require postponement / modification depending on schedule.


28
New cards

What are some drug ass. complications?

  • Cumulative cardiotox (DCM) —> doxorubicin

  • Sterile haemorrhagic cystitis —> cyclophosphamide

    • prevention —> furosemide, incr drinking, freq outdoor access (incr urine output to reduce contact w/ bladder)

  • Hepatotox —> lomustine (dogs)

  • Nephrotoxicity —> cisplatin, doxorubicin (cats), lomustine (dogs)

  • Fatal non-cadiogenic pulmonary oedema (cisplatin)

  • Fatal CNS signs


29
New cards

What can reduce the risk of hepatotoxicity?

SAM-E

30
New cards

What is being shown here?


Extravasation

  • ALWAYS use a cleanly placed first stick catheter, never leave unsupervised & flush before removal

  • Monitor for any swelling, discomfort, changes in resistance to injection or rate of infusion

  • Do not use syringe driver / pump

  • Flush catheters appropriately before cath removal


31
New cards

What are the txs for extravasations?

  • Doxorubicin / epirubicin / actinomycin D —> apply cold packs

  • consider (immediate) surgical debridement

  • vincristine / vinblastine —> apply warm compresses


32
New cards

What are the features of metronomic chemotherapy?

  • Daily low dose chemotherapy

    • Direct action on tumour cells & stim immune response → angiogenesis

  • Prevent local recurrence soft tissue sarcoma

  • Slow metastatic dx haemangiosarcoma

  • Usually low dose cyclophoshamide w/ piroxicam (or other NSAIDs)

    • monitoring via haematology & urine dipstick


33
New cards

What is MOA of Receptor Tyrosine Kinase?

  • Inhibit the activation of specific signalling pathways involved in specific types of cancer

  • Two oral drugs targeting the RTK KIT (toceranib and masitinib) licensed for tx of mast cell tumours in dogs

    • licenced for incomplete excision & generally used for metastatic dx


34
New cards

What side effects can be seen with receptor tyrosine kinase inhibitors?

  • D+ & anorexia

    • 35 – 45 %, but only severe in 10%

    • Many owners report soft stools

    • Usually managed by tx pauses

  • Bone marrow suppression

    • Around 10 % not typically severe